We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+1.01%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
-$349K
Cap. Flow
+$2.51M
Cap. Flow %
1.53%
Top 10 Hldgs %
67.19%
Holding
47
New
3
Increased
23
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.09M
2
UNH icon
UnitedHealth
UNH
+$4.23M
3
AMGN icon
Amgen
AMGN
+$2.56M
4
TMO icon
Thermo Fisher Scientific
TMO
+$2.45M
5
UFPT icon
UFP Technologies
UFPT
+$2.42M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$4.06M
2
ELV icon
Elevance Health
ELV
+$3.84M
3
GILD icon
Gilead Sciences
GILD
+$3.81M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$2.96M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$1.47M 0.9%
148,207
-104,100
-41% -$1.07M
NAMS icon
27
NewAmsterdam Pharma
NAMS
$3.29B
$1.46M 0.89%
75,794
+53,400
+238% +$1.07M
KRYS icon
28
Krystal Biotech
KRYS
$9.61B
$1.4M 0.85%
7,624
+1,000
+15% +$168K
BBIO icon
29
BridgeBio Pharma
BBIO
$16.3B
$1.35M 0.83%
53,432
+15,591
+41% +$426K
ACLX
30
DELISTED
Arcellx
ACLX
$1.24M 0.76%
22,496
+5,000
+29% +$272K
HRMY icon
31
Harmony Biosciences
HRMY
$2.28B
$1.05M 0.64%
34,900
-135,100
-79% -$4.06M
IMCR icon
32
Immunocore
IMCR
$1.74B
$806K 0.49%
23,778
-17,121
-42% -$873K
AUTL
33
Autolus Therapeutics
AUTL
$633M
$787K 0.48%
226,145
+129,800
+135% +$560K
MORF
34
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$688K 0.42%
20,199
+5,247
+35% +$155K
PHVS icon
35
Pharvaris
PHVS
$2.41B
$645K 0.39%
+34,328
New +$699K
MGNX icon
36
MacroGenics
MGNX
$252M
$609K 0.37%
143,407
+94,100
+191% +$916K
CABA icon
37
Cabaletta Bio
CABA
$455M
$481K 0.29%
64,321
-13,219
-17% -$162K
MRSN
38
DELISTED
Mersana Therapeutics
MRSN
$372K 0.23%
7,396
+3,396
+85% +$246K
AKRO
39
DELISTED
Akero Therapeutics
AKRO
– –
-24,432
Closed -$617K
CYTK icon
40
Cytokinetics
CYTK
$10.7B
– –
-14,000
Closed -$982K
ELV icon
41
Elevance Health
ELV
$84.6B
– –
-7,400
Closed -$3.84M
EXAS
42
DELISTED
Exact Sciences
EXAS
– –
-16,120
Closed -$1.11M
GILD icon
43
Gilead Sciences
GILD
$169B
– –
-52,000
Closed -$3.81M
INSP icon
44
Inspire Medical Systems
INSP
$1.73B
– –
-4,782
Closed -$1.03M
MDGL icon
45
Madrigal Pharmaceuticals
MDGL
$12.2B
– –
-3,539
Closed -$945K
FUSN
46
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-138,836
Closed -$2.96M
SWAV
47
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-4,751
Closed -$1.55M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

HealthInvest Partners's Q2 2024 Portfolio in Review

As of Q2 2024, HealthInvest Partners held 47 positions worth $164M, down 0.21% from $164M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

HealthInvest Partners's Q2 2024 filing shows 3 new, 23 increased, 11 reduced and 9 closed positions. Its largest new stake was UFP Technologies: 9,800 shares worth $2.59M. The largest sale was Harmony Biosciences, an estimated $4.06M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q2 2024 buy was UFP Technologies: 9,800 shares worth $2.59M.
  • HealthInvest Partners added most to Eli Lilly in Q2 2024, an estimated $5.09M increase.
  • HealthInvest Partners's biggest Q2 2024 reduction was Harmony Biosciences, cutting an estimated $4.06M.
  • HealthInvest Partners fully exited Elevance Health in Q2 2024, selling an estimated $3.84M.
  • HealthInvest Partners's ten largest holdings make up 67% of its $164M portfolio in Q2 2024.
  • HealthInvest Partners opened 3 new positions and closed 9 in Q2 2024.
  • HealthInvest Partners's portfolio value fell 0.21% quarter-over-quarter to $164M.

Based on HealthInvest Partners's 13F filing for Q2 2024, filed 14 Aug 2024.